The prognostic value of the suPARnosticELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms-3

<p><b>Copyright information:</b></p><p>Taken from "The prognostic value of the suPARnosticELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms"</p><p>http://www.biomedcentral.com/1471-2334/7/134</p><p>BMC Infectious Diseases 2007;7():134-134.</p><p>Published online 16 Nov 2007</p><p>PMCID:PMC2216028.</p><p></p> G transition (— A/A; ------ A/G; - - - G/G). + indicate censored

Restriction pattern by Eci-1 and MspA1 l fragmentation of the uPAR promoter sequence

<p><b>Copyright information:</b></p><p>Taken from "The prognostic value of the suPARnosticELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms"</p><p>http://www.biomedcentral.com/1471-2334/7/134</p><p>BMC Infectious Diseases 2007;7():134-134.</p><p>Published online 16 Nov 2007</p><p>PMCID:PMC2216028.</p><p></p> Lane 1 and 10, 100 bp-marker; lane 2 non digested PCR-product, lane 3–5 Eci-1 fragmentation of the -118 G to A transition (G/G; G/A and A/A), lane 6–8 MspA1 l fragmentation of the -465 A to G transition (A/A; A/G and G/G); lane 9 Eci-1 and MspA1 l fragmentation of a double heterozygote individual

Kaplan Meyer plot of 81 patients divided into tertiles based on suPAR levels

<p><b>Copyright information:</b></p><p>Taken from "The prognostic value of the suPARnosticELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms"</p><p>http://www.biomedcentral.com/1471-2334/7/134</p><p>BMC Infectious Diseases 2007;7():134-134.</p><p>Published online 16 Nov 2007</p><p>PMCID:PMC2216028.</p><p></p> Patients with low suPAR (N = 27, thin line), median suPAR (N = 27, median thick line) and high suPAR (N = 27, thick line)

90-day survival from Gram negative sepsis according to disease severity

<p><b>Copyright information:</b></p><p>Taken from "Common TNF-α, IL-1β, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis"</p><p>http://www.biomedcentral.com/1471-2334/7/108</p><p>BMC Infectious Diseases 2007;7():108-108.</p><p>Published online 18 Sep 2007</p><p>PMCID:PMC2034565.</p><p></p> Log-rank test: P = 0.014

Risk of an incident hospital diagnosis of depression according to the suPAR level.

<p>Risk of an incident hospital diagnosis of depression according to the suPAR level.</p

Kaplan-Meier plot with antidepressants as outcome and the suPAR level quartiles as explanatory variables (n = 9305).

<p>The 4^th quartile is the highest values. Log-rank test: p<0.0001.</p

Soluble urokinase plasminogen activator receptor (suPAR) (ng/ml) in blood donors according to sex and age.

<p>Soluble urokinase plasminogen activator receptor (suPAR) (ng/ml) in blood donors according to sex and age.</p

Effect¹ of previous use of antidepressants on log2-transformed suPAR.

1<p>Estimates are from linear regressions adjusting for age (continuous).</p><p>Effect^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0110555#nt102" target="_blank">1</a>} of previous use of antidepressants on log2-transformed suPAR.</p

Risk¹ of incident use of antidepressants according to the suPAR level.

1<p>Estimates are hazard ratios from Cox regression analyses stratified by sex and with age as the underlying time scale. Purchase of antidepressants is used as proxy for depression. The analysis is performed both with and without adjustment for other medication.</p><p>Risk^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0110555#nt101" target="_blank">1</a>} of incident use of antidepressants according to the suPAR level.</p

Baseline characteristics for HIV-infected patients not infected through intravenous drug use (IDU).

<p><b>Abbreviations:</b> cART: Combination antiretroviral treatment; BMI: Body mass index.</p